Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy.

S Bowyer; P Prithviraj; Paul Lorigan; J Larkin; G McArthur; V Atkinson; M Millward; M Khou; S Diem; S Ramanujam; B Kong; E Liniker; A Guminski; P Parente; M C Andrews; S Parakh; J Cebon; G V Long; M S  Carlino; O Klein

doi:10.1038/bjc.2016.107

Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy.

S Bowyer, P Prithviraj, Paul Lorigan, J Larkin, G McArthur, V Atkinson, M Millward, M Khou, S Diem, S Ramanujam, B Kong, E Liniker, A Guminski, P Parente, M C Andrews, S Parakh, J Cebon, G V Long, M S Carlino, O Klein

The Royal Marsden NHS Foundation Trust

Research output: Contribution to journal › Article › peer-review

Original language	English
Article number	10.1038/bjc.2016
Pages (from-to)	1084
Number of pages	1089
Journal	British Journal of Cancer
Volume	114
Issue number	10
DOIs	https://doi.org/10.1038/bjc.2016.107
Publication status	Published - 10 May 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/bjc.2016.107

Cite this

Bowyer, S., Prithviraj, P., Lorigan, P., Larkin, J., McArthur, G., Atkinson, V., Millward, M., Khou, M., Diem, S., Ramanujam, S., Kong, B., Liniker, E., Guminski, A., Parente, P., Andrews, M. C., Parakh, S., Cebon, J., Long, G. V., Carlino, M. S., & Klein, O. (2016). Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. British Journal of Cancer, 114(10), 1084. Article 10.1038/bjc.2016. https://doi.org/10.1038/bjc.2016.107

@article{5899a510e096410f82ad9bb58ce8b604,

title = "Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy.",

author = "S Bowyer and P Prithviraj and Paul Lorigan and J Larkin and G McArthur and V Atkinson and M Millward and M Khou and S Diem and S Ramanujam and B Kong and E Liniker and A Guminski and P Parente and Andrews, \{M C\} and S Parakh and J Cebon and Long, \{G V\} and Carlino, \{M S\} and O Klein",

year = "2016",

month = may,

day = "10",

doi = "10.1038/bjc.2016.107",

language = "English",

volume = "114",

pages = "1084",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Springer Nature",

number = "10",

}

Bowyer, S, Prithviraj, P, Lorigan, P, Larkin, J, McArthur, G, Atkinson, V, Millward, M, Khou, M, Diem, S, Ramanujam, S, Kong, B, Liniker, E, Guminski, A, Parente, P, Andrews, MC, Parakh, S, Cebon, J, Long, GV, Carlino, MS & Klein, O 2016, 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy.', British Journal of Cancer, vol. 114, no. 10, 10.1038/bjc.2016, pp. 1084. https://doi.org/10.1038/bjc.2016.107

TY - JOUR

T1 - Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy.

AU - Bowyer, S

AU - Prithviraj, P

AU - Lorigan, Paul

AU - Larkin, J

AU - McArthur, G

AU - Atkinson, V

AU - Millward, M

AU - Khou, M

AU - Diem, S

AU - Ramanujam, S

AU - Kong, B

AU - Liniker, E

AU - Guminski, A

AU - Parente, P

AU - Andrews, M C

AU - Parakh, S

AU - Cebon, J

AU - Long, G V

AU - Carlino, M S

AU - Klein, O

PY - 2016/5/10

Y1 - 2016/5/10

UR - https://www.scopus.com/pages/publications/84967185844

U2 - 10.1038/bjc.2016.107

DO - 10.1038/bjc.2016.107

M3 - Article

SN - 0007-0920

VL - 114

SP - 1084

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 10

M1 - 10.1038/bjc.2016

ER -

Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy.

UN SDGs

Access to Document

Other files and links

Cite this